Retrophin Inc (NASDAQ:RTRX) Insider Sells $17,826.30 in Stock

Share on StockTwits

Retrophin Inc (NASDAQ:RTRX) insider Noah L. Rosenberg sold 870 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $20.49, for a total value of $17,826.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

RTRX stock opened at $19.88 on Friday. The stock has a market capitalization of $858.02 million, a PE ratio of -9.42 and a beta of 0.86. Retrophin Inc has a 12-month low of $8.98 and a 12-month high of $21.92. The company has a current ratio of 5.97, a quick ratio of 5.88 and a debt-to-equity ratio of 0.92. The stock’s 50 day simple moving average is $19.03 and its 200 day simple moving average is $16.31.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.58). The business had revenue of $48.43 million for the quarter, compared to analysts’ expectations of $48.50 million. Retrophin had a negative return on equity of 39.84% and a negative net margin of 49.13%. On average, research analysts predict that Retrophin Inc will post -1.56 earnings per share for the current year.

RTRX has been the topic of a number of research analyst reports. ValuEngine downgraded Retrophin from a “strong-buy” rating to a “buy” rating in a report on Friday, April 17th. BTIG Research assumed coverage on Retrophin in a research report on Tuesday, June 16th. They issued a “buy” rating and a $25.00 price target on the stock. BMO Capital Markets dropped their price target on Retrophin from $34.00 to $31.00 in a research report on Monday, July 13th. Canaccord Genuity reissued a “buy” rating and issued a $26.00 price target on shares of Retrophin in a research report on Tuesday, May 19th. Finally, Zacks Investment Research raised Retrophin from a “hold” rating to a “strong-buy” rating and set a $23.00 price target on the stock in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Retrophin has an average rating of “Buy” and an average price target of $27.25.

Institutional investors and hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its stake in Retrophin by 103.1% during the 1st quarter. Nisa Investment Advisors LLC now owns 1,970 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 1,000 shares during the last quarter. Great West Life Assurance Co. Can purchased a new stake in Retrophin during the 4th quarter valued at $50,000. SG Americas Securities LLC purchased a new stake in Retrophin during the 1st quarter valued at $122,000. Calton & Associates Inc. purchased a new stake in Retrophin during the 1st quarter valued at $158,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Retrophin by 256.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,734 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 5,564 shares in the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Featured Article: Convertible Shares

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Truist Securiti Comments on KAR Auction Services Inc’s Q3 2020 Earnings
Truist Securiti Comments on KAR Auction Services Inc’s Q3 2020 Earnings
KBR, Inc.  Forecasted to Earn Q3 2020 Earnings of $0.41 Per Share
KBR, Inc. Forecasted to Earn Q3 2020 Earnings of $0.41 Per Share
Transocean Target of Unusually Large Options Trading
Transocean Target of Unusually Large Options Trading
Home Depot  to Release Quarterly Earnings on Tuesday
Home Depot to Release Quarterly Earnings on Tuesday
Laboratory Corp. of America  Downgraded by ValuEngine
Laboratory Corp. of America Downgraded by ValuEngine
State of Michigan Retirement System Has $696,000 Position in Visteon Corp
State of Michigan Retirement System Has $696,000 Position in Visteon Corp


© 2006-2020 Ticker Report